南水北调中线工程与河南省区域联合治理机制研究

南水北调工程是一个典型跨主体、跨行业、跨期和跨行政区域的水利工程,繁杂的工程建设以及信息不对称和管理认识上的滞后,管理者往往低估了各种潜在风险对工程的影响。本文从南水北调工程与河南区域关系特征入手,分析了两者间存在的问题,在此基础上,从理顺治理结构、探索具有激励相容的工程区域合作模式、选择可行的政策工具组合、从博弈论角度构建工程区域关系、引入工程影响评价机制等角度提出了对策建议。     

依法行政若干问题的思考

突破制约依法行政的瓶颈,迫切要求推动理念创新,以引领依法行政的实践。本文认为,依法行政的功能不仅是治官、治权,更是深化政治体制改革、发展社会主义民主政治的重要方面;适应依法行政从既靠政策又靠法律向靠政策,更靠法律的转变,要依法制定政策,推动政策的法律转化;服务型政府建设要体现依法行政的要求,重视公共服务制度化,坚持管理与服务并重;我国的改革已经从边改革边完善制度阶段进入了依法深化改革的新阶段,改革创新应当在宪法法律框架内进行;培育法治社会,要把法制宣传教育提升到国家公民教育的高度来认识;积极推动依法行政动力机制的转型,构建政府自上而下推动与社会由外而内推动有机结合的依法行政动力机制。     

基于“脆弱性-能力”综合视角的公共安全评价框架:形成与范式

国际社会的公共安全评估框架在不断发展之中,从单独的脆弱性视角或能力视角进行公共安全评价,到形成较为完善的公共安全评价的脆弱性-能力综合视角,大体经历了三个过程。本文阐述了在脆弱性-能力综合视角下的公共安全评价主要研究内容,以及该评价框架的范式与应用。脆弱性-能力综合视角的评价框架研究,把质性研究与定量方法相结合,从脆弱性和应对能力综合的视角出发,通过引入系统动力学,提出了一种公共安全与公共危机管理动态评价的新思路,构建了一个公共安全与公共危机管理的动态评价和识别框架,为公共安全评价工具和方法提供新的视角和前提。     

城市管理专业的人才培养目标与模式

城市管理专业是随着当代中国城市发展导致的城市管理专业化趋势及其对城市管理专门人才的急需而发展起来的一个新兴专业。城市管理的综合性特点要求城市管理专业的课程设置注重综合,强调应用,并实现文、理、工科相结合,其专业基础课应横跨管理学和城市科学两大学科基础,专业课则应突出城市管理作为一个独立学科、综合性专业的特点。完善符合城市管理专业应用型复合型人才培养需要的教学体系,当前的重点是强化实践教学,建立一体化的实践教学体系,相应地需要创新师资队伍,促进教师实践能力的提升和素质的优化,以保障城市管理专业教学体系高质量地运行。     

应用为核心实现政务信息资源整会共享

2006年之前,北京市丰台区电子政务信息资源的开发建设缺乏全区的统一规划,信息数据的管理维护仍处于各部门自成体系的状态.自部门信息仅限于纵向交流,政务资源没有联通交换,处于信息资源整合的初期阶段.针对全区各项业务工作对信息化的实际需求,进一步提升政府的整体效能和城市管理水平,丰台区着手构建一体化信息共享交换平台,突出以电子政务应用驱动政务信息资源整合、以资源整合支撑电子政务应用,逐步提高信息化服务政府办公、社会安全、城市管理、公共服务的能力.     

Orthopedic devices; reclassification of the intervertebral body fusion device. Final rule

The Food and Drug Administration (FDA) is reclassifying intervertebral body fusion devices that contain bone grafting material, from class III (premarket approval) into class II (special controls), and retain those that contain any therapeutic biologic (e.g., bone morphogenic protein) in class III. Elsewhere in this issue of the Federal Register, FDA is announcing the availability of a guidance document that will serve as the special control for this device. This reclassification is based upon on the recommendation of the Orthopaedic and Rehabilitation Devices Panel (the Panel).     

Over-the-counter vaginal contraceptive and spermicide drug products containing nonoxynol 9; required labeling. Final rule

The Food and Drug Administration (FDA) is issuing a final rule establishing new warning statements and other labeling information for all over-the-counter (OTC) vaginal contraceptive drug products (also known as spermicides, hereinafter referred to as vaginal contraceptives or vaginal contraceptives/spermicides) containing nonoxynol 9 (N9). These warning statements will advise consumers that vaginal contraceptives/spermicides containing N9 do not protect against infection from the human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS), or against getting other sexually transmitted diseases (STDs). The warnings and labeling information will also advise consumers that use of vaginal contraceptives and spermicides containing N9 can irritate the vagina and rectum and may increase the risk of getting the AIDS virus (HIV) from an infected partner. This final rule is part of FDA's ongoing review of OTC drug products. FDA is issuing this final rule after considering public comments on its proposed regulation, and all relevant data and information on N9 that have come to our attention.     

Amendment to the current good manufacturing practice regulations for finished pharmaceuticals. Direct final rule

The Food and Drug Administration (FDA) is amending certain regulations as the first phase of an incremental approach to modifying the current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. We are amending the regulations to modernize or clarify some of the CGMP requirements, as well as harmonize some of the CGMP requirements with those of other foreign regulators and other FDA regulations. These amendments are also consistent with current industry practice. We are taking this action as part of our continuing effort to revise outdated regulations without diminishing public health protection. We are issuing a direct final rule for this action because FDA expects there will be no significant adverse comments on these amendments. Elsewhere in this issue of the Federal Register, we are publishing a companion proposed rule, under our usual notice-and-comment rulemaking procedures, to provide a procedural framework to finalize the rule in the event the agency receives any significant adverse comments and withdraws this direct final rule. The companion proposed rule and direct final rule are substantively identical.     

National vaccine injury compensation program: calculation of average cost of a health insurance policy. Final rule

Subtitle 2 of Title XXI of the Public Health Service Act, as enacted by the National Childhood Vaccine Injury Act of 1986, as amended (the Act), governs the National Vaccine Injury Compensation Program (VICP). The VICP, administered by the Secretary of Health and Human Services (the Secretary), provides that a proceeding for compensation for a vaccine-related injury or death shall be initiated by service upon the Secretary, and the filing of a petition with the United States Court of Federal Claims (the Court). In some cases, the injured individual may receive compensation for future lost earnings, less appropriate taxes and the "average cost of a health insurance policy, as determined by the Secretary." The final rule establishes the new method of calculating the average cost of a health insurance policy and determines the amount of the average cost of a health insurance policy to be deducted from the compensation award.     

Changes in the regulation of iodine crystals and chemical mixtures containing over 2.2 percent iodine. Final rule

This rulemaking changes the regulation of the listed chemical iodine under the chemical regulatory provisions of the Controlled Substances Act (CSA). The Drug Enforcement Administration (DEA) believes that this action is necessary to remove deficiencies in the existing regulatory controls, which have been exploited by drug traffickers who divert iodine (in the form of iodine crystals and iodine tincture) for the illicit production of methamphetamine in clandestine drug laboratories. This rulemaking moves iodine from List II to List I; reduces the iodine threshold from 0.4 kilograms to zero kilograms; adds import and export regulatory controls; and controls chemical mixtures containing greater than 2.2 percent iodine. This rulemaking establishes regulatory controls that will apply to iodine crystals and iodine chemical mixtures that contain greater than 2.2 percent iodine. This regulation therefore controls iodine crystals and strong iodine tinctures/solutions (e.g., 7 percent iodine) that do not have common household uses and instead have limited application in livestock, horses, and for disinfection of equipment. Household products such as 2 percent iodine tincture/solution and household disinfectants containing iodine complexes will not be adversely impacted by this regulation. Additionally, the final rule exempts transactions of up to one-fluid-ounce (30 ml) of Lugol's Solution. Persons handling regulated iodine materials are required to register with DEA, are subject to the import/export notification requirements of the CSA, and are required to maintain records of all regulated transactions involving iodine regardless of size.